Latest / Breaking News To Trading Moves
Biogen and Apellis: Biotech Acquisition Market Dynamics
Biogen Buys Apellis: Rare Disease Biotech
Biogen is making one of the bigger biotech moves on the tape, agreeing to buy Apellis for about $5.6 billion in cash. The key trading angle is that this can lift sentiment around commercial-stage biotech and rare disease names that could be seen as future takeover candidates, while also putting pressure on Biogen itself as traders weigh the size, financing, and execution risk of the deal.
Winners
Rare disease biotech takeover candidates
A large-premium biotech deal can make investors re-rate other U.S.-listed rare disease companies with approved…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.